Regeneron Wins FDA Nod for Extended Eylea HD Dosing Interval

FDA approved extending Eylea HD dosing interval to 20 weeks, permitting longer dosing for wAMD and DME patients. The change increases treatment flexibility and could reduce treatment burden, supporting Regeneron's effort to partially offset declining Eylea sales and improve patient retention; likely modestly positive for REGN's revenue trajectory but not a transformative event.

Analysis

FDA approved extending Eylea HD dosing interval to 20 weeks, permitting longer dosing for wAMD and DME patients. The change increases treatment flexibility and could reduce treatment burden, supporting Regeneron's effort to partially offset declining Eylea sales and improve patient retention; likely modestly positive for REGN's revenue trajectory but not a transformative event.